tiprankstipranks
Charlotte's Web Holdings (DE:6CW)
FRANKFURT:6CW

Charlotte's Web Holdings (6CW) Price & Analysis

0 Followers

6CW Stock Chart & Stats

€0.21
€0.03(19.08%)
At close: 4:00 PM EDT
€0.21
€0.03(19.08%)

Bulls Say, Bears Say

Bulls Say
Manageable LeverageLow debt relative to equity reduces balance-sheet pressure and provides more financial flexibility than a highly levered structure, helping the company withstand continued operating weakness while it works toward restoring profitability.
Diversified Product And Distribution ModelA broad product range and dual-channel model diversify revenue sources across consumer needs and purchasing venues. This structure can support longer-term reach and reduce reliance on one product category or route to market.
Positive Gross Margin BaseThe company retains meaningful gross profit after product costs, indicating that its branded products generate underlying contribution before operating expenses. Better cost discipline or scale could allow this margin base to support eventual operating improvement.
Bears Say
Declining RevenuePersistent revenue contraction signals weakening demand, distribution, or brand momentum. Without a durable return to growth, fixed operating costs are harder to absorb and the company has less opportunity to leverage its product portfolio.
Severe Operating LossesDeep operating and net losses show that gross profit is insufficient to cover the company’s expense base. Continued losses constrain reinvestment capacity and increase execution risk until management can achieve sustainable operating break-even.
Persistent Cash BurnNegative operating and free cash flow means the business is not self-funding and remains dependent on available liquidity or external financing. Continued cash consumption could reduce strategic flexibility even though current leverage is manageable.

Charlotte's Web Holdings News

6CW FAQ

What was Charlotte's Web Holdings’s price range in the past 12 months?
Charlotte's Web Holdings lowest stock price was €0.05 and its highest was €0.79 in the past 12 months.
    What is Charlotte's Web Holdings’s market cap?
    Charlotte's Web Holdings’s market cap is €77.23M.
      When is Charlotte's Web Holdings’s upcoming earnings report date?
      Charlotte's Web Holdings’s upcoming earnings report date is Nov 16, 2026 which is in 83 days.
        How were Charlotte's Web Holdings’s earnings last quarter?
        Charlotte's Web Holdings released its earnings results on Aug 13, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
          Is Charlotte's Web Holdings overvalued?
          According to Wall Street analysts Charlotte's Web Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Charlotte's Web Holdings pay dividends?
            Charlotte's Web Holdings does not currently pay dividends.
            What is Charlotte's Web Holdings’s EPS estimate?
            Charlotte's Web Holdings’s EPS estimate is -0.02.
              How many shares outstanding does Charlotte's Web Holdings have?
              Charlotte's Web Holdings has 271,291,530 shares outstanding.
                What happened to Charlotte's Web Holdings’s price movement after its last earnings report?
                Charlotte's Web Holdings reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 7.08%.
                  Which hedge fund is a major shareholder of Charlotte's Web Holdings?
                  Currently, no hedge funds are holding shares in DE:6CW
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Charlotte's Web Holdings Stock Smart Score

                    Company Description

                    Charlotte's Web Holdings

                    Charlotte's Web Holdings, Inc. operates comprehensively in the hemp-derived cannabidiol (CBD) wellness market, covering cultivation, manufacturing, marketing, and sales. The company's extensive product line features liquid hemp extract oil tinctures, a variety of gummies designed for benefits such as sleep, stress relief, immune support, and post-exercise recovery, as well as easy-to-use capsules, topical CBD creams, and lotions. They also offer specialized products for pets. These offerings are available under recognized brands including Charlotte's Web, CBD Medic, CBD Clinic, and Harmony Hemp. Each product is formulated with naturally occurring phytocannabinoids, such as CBD, cannabichromene, cannabigerol, and cannabinol, alongside beneficial terpenes, flavonoids, and other hemp compounds. Distribution occurs through various channels, including brick-and-mortar retail locations, healthcare providers, and direct-to-consumer sales via their online platform. The company is committed to advancing cannabinoid research; its CW Labs science division collaborates with the University at Buffalo's Center for Integrated Global Biomedical Sciences on a dedicated research program, and it also maintains a scientific partnership with McLean Hospital. Founded in 2013 as Stanley Brothers Holdings Inc., the company rebranded to Charlotte's Web Holdings, Inc. in July 2018 and is headquartered in Denver, Colorado.

                    Charlotte's Web Holdings (6CW) Earnings & Revenues

                    6CW Earnings Call

                    Q4 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call emphasized several transformative, strategic positives — a balance-sheet‑clearing BAT transaction with fresh capital, federal Medicare pilot eligibility (Substance Access BEI) allowing full‑spectrum CBD access into accountable care channels, meaningful clinical progress via DeFloria's Phase II clearance, substantial cost reductions (SG&A down ~21% YoY and ~44.5% over two years), and improved operating loss and margin runways. These positives are tempered by ongoing regulatory uncertainty (including a potential November 2026 hemp provision that could severely constrain the market), persistent net losses (Q4 net loss $11.4M; full‑year net loss ~$29.7M), a nonrecurring $1.3M inventory charge that depressed reported margins, and liquidity dependence on shareholder approval of the BAT transaction. On balance, the call conveyed constructive momentum and multiple high‑impact catalysts that materially improve the company’s strategic position, while acknowledging meaningful near‑term risks and the gradual timing of revenue realization from Medicare pilots.View all DE:6CW earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Canopy Growth
                    Leef Brands
                    Curaleaf Holdings
                    MediPharm Labs
                    Avicanna
                    Popular Stocks